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TABLE I. Subjects’ characteristics
Characteristic Control Asthma
P value
(2-tailed)
Sample size, n (male/female) 16 (8/8) 16 (10/6) .72
Age (y) 26.6 6 5.2 27.8 6 6.1 .58
BMI (kg/m2) 24.7 6 3.5 24.6 6 4.6 .96
FEV1 prebronchodilator
(% predicted)
96.3 6 12.1 81.3 6 15.1 .004
FEV1 postbronchodilator
(% predicted)
100.9 6 13.2 91.6 6 12.6 .051
FENO (ppb) 17.9 6 8.5 37.3 6 40.9 .16
Asthma Control
Questionnaire score
0.1 6 0.2 1.0 6 0.4 <.001
Allergies (% yes) 18.8 57.1 .03
SABA usage (%) 0.0 56.3 <.001
ICS usage (%) 0.0 18.8 <.001
Combination ICS 1 LABA
usage (%)
0.0 43.8 <.001
Physical activity, steps/d 10,711 6 2,675 11,125 6 5,487 .79
Fitness (relative V
:
O2max)
(mL/kg/min % predicted)
106.1 6 15.9 97.1 623.3 .21
Mean arterial pressure
(mmHg)
79 6 5 82 6 10 .34
Heart rate (bpm) 55.7 6 5.8 59.3 6 6.0 .10
Total cholesterol (mmol/L) 3.7 6 0.9 3.9 6 1.4 .86
HDL (mmol/L) 1.4 6 0.2 1.4 6 0.4 .92
Fasting glucose (mmol/L) 3.9 6 0.4 3.9 6 0.4 .81
CRP (mg/L) 2.3 6 3.83 3.6 6 3.5 .46
IL-6 (pg/mL) 8.6 6 5.9 6.9 6 3.5 .35
TNF-a (pg/mL) 16.5 6 5.1 16.3 6 2.8 .91
Values are mean 6 SD unless indicated otherwise.
BMI, Body mass index; bpm, beats per minute; CRP, C-reactive protein; FENO, fraction
of exhaled nitric oxide; HDL, high-density lipoprotein; ICS, inhaled corticosteroid;
LABA, long-acting beta-agonist; SABA, short-acting beta-agonist; TNF-a, tumor
necrosis factor-alpha; V
:
O2, rate of oxygen consumption.
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Physical activity, fitness, and vascular health
in patients with asthma
To the Editor:
Patients with asthma are at an increased risk of cardiovascular
disease (CVD),1 and increased systemic inflammation associated
with asthma may play a role. High levels of the proinflammatory
cytokines IL-6, C-reactive protein, and tumor necrosis factor-
alpha are elevated in asthma, and all are associated with increased
CVD risk.2,3 Reduced endothelial vasodilation is seen in early
stages of CVD development and is predictive of CVD.4 Patients
with asthma have reduced endothelial function and increased
arterial stiffness than do those without asthma.5,6 Systemic
inflammation impairs endothelial function7 and increases arterial
stiffness,8 but it is unknown whether there is a connection be-
tween systemic inflammation, vascular function, and arterial stiff-
ness in subjects with asthma. Importantly, patients with asthma
are usually more sedentary than their age-matched counterparts,9
and inactivity has been linked to increased inflammation, im-
paired vascular function, and increased CVD risk.10 Accordingly,
we evaluated parameters of vascular function and systemic
inflammation in patients with and without asthma matched for
physical activity and aerobic fitness. We hypothesized that those
with asthma would be associated with higher systemic inflamma-
tion, impaired endothelial function, and increased arterial stiff-
ness as compared with controls even when matched for physical
activity and aerobic fitness.
For complete methodology, see this article’s Methods section
in the Online Repository at www.jacionline.org. Briefly, patients
with asthma (18-45 years, n 5 16) with a body mass index of 30
kg/m2 or less were recruited and compared with age-, body mass
index-, physical activity-, and fitness-matched control subjects
(n5 16) without asthma. Asthma diagnosis was based on history
and 1) 12% or more and 200 mL improvement in FEV1 postbron-
chodilator, 2) a positive methacholine challenge (PC20 <_ 4 mg/
mL), or 3) 10% or more decrease in FEV1 after an exercise chal-
lenge. Controls demonstrated negative responses to all the 3 tests
described above. A cardiopulmonary exercise test was performed 2015 The Authors. Published by Elsevier, Inc. on behalf of the Academy of Allergy,
Asthma& Immunology. This is an open access article under the CCBY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/4.0/).to determine aerobic fitness (V
:
O2max). Physical activity was
quantified as the number of steps taken over 3 days by a physical
activity monitor. Vascular function was evaluated by flow-
mediated dilation (FMD) adjusted for shear stress, and arterial
stiffness was evaluated by the pulse wave velocity (PWV)
between the radial and the carotid arteries using applanation
tonometry. A blood sample was taken for analysis of systemic
inflammatory markers (ie, IL-6, C-reactive protein, and tumor
necrosis factor-alpha), fasting glucose, and cholesterol levels.
The Asthma Control Questionnaire indicated that patients with
asthma were within the ranges of controlled to partly controlled
asthma. There were no between-group differences in fraction of
exhaled nitric oxide, postbronchodilator FEV1, indices of blood
pressure, fasting glucose, lipid profiles, or systemic inflammatory
markers (see Table I). Although therewere no differences in endo-
thelial function (FMD) or microvascular function (velocity time
integral) between subjects with and without asthma, subjects
with asthma had significantly higher arterial stiffness than did
those without asthma (Fig 1). There was no relationship between
FMD and markers of systemic inflammation in asthma (see Fig
E1, A-C, in this article’s Online Repository at www.jacionline.
org); however, there was a strong positive correlation between
PWV and IL-6 in subjects with asthma, but no associations
were observed between PWV and tumor necrosis factor-alpha
or C-reactive protein (see Fig E1, E and F).
Whenmatched for age, bodymass index, physical activity, and
aerobic fitness, those with asthma and controls had similar
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FIG 1. Endothelial function (A), microvascular function (B), and arterial
stiffness (C) among controls and patients with asthma. Asterisk indicates
P < .05 between groups. SSRHtotal, Total shear stress after reactive
hyperemia; VTI, velocity time integral.
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inflammation. Those with asthma had significantly higher
arterial stiffness than did those without asthma, suggesting that
structural changes within the vessel walls that are independent of
physical activity, aerobic fitness, and inflammation occur in
asthma.
Previous work found that as compared with controls, thosewith
asthma have reduced vascular function6 and increased arterial
stiffness.5 However, these studies did not report fitness or physical
activity levels, and it is likely that those with asthma were less
active.9 As a result, subjects with asthmawould probably have ex-
hibited lower fitness and impaired vascular health. In addition,
previous work6 had not normalized vascular reactivity to its stim-
ulus (ie, shear stress). Our findings indicate that whenmatched for
fitness or physical activity, those with asthma do not appear tohave reduced vascular function as compared with healthy con-
trols. However, the increase in arterial stiffness in those with
asthma is related to lung disease, and not secondary to reduced
physical activity or fitness.
Although increased levels of systemic inflammation are known
to adversely affect vascular function and arterial stiffness,7,8 sys-
temic inflammation was similar in both those with asthma and
controls. These findings indicate that the increase in PWVin those
with asthma relative to controls occurred independent of systemic
inflammation. There was an association between IL-6 and arterial
stiffness within those with asthma, suggesting that systemic
inflammation may be related to arterial stiffness in those with
asthma; however, it does not explain the elevation in PWV
relative to controls.
All subjects in the present study were carefully screened, and
it could be argued that these stringent inclusion criteria may have
resulted in a sample inadequate to detect between-group
differences in FMD. Our study was powered to detect a 10%
difference in FMD between those with asthma and controls,6
corresponding to a large increase in the relative risk of CVD
(for more details, see this article’s Online Repository at www.
jacionline.org). More importantly, the mean value for vascular
function between those with asthma and controls was very
similar, and a power calculation indicates that 340 subjects
would have been required to detect a difference, which would
have been well below any clinical significance. Beta agonists
may modify sympathetic nerve activity, which could affect
PWV and may explain the difference observed between those
with asthma and controls. In the present study, all subjects
with asthma withheld beta agonists for 12 hours before testing,
and thus acute effects were controlled; however, chronic effects
of asthma medication on vascular health are mostly still un-
known. Furthermore, the age criteria in the present study did
not allow for the evaluation of the influence of age or asthma
duration on vascular health and further research is needed in
this area.
In conclusion, stiffening of the systemic arteries appears to
occur independently of physical activity, inflammation, and
fitness in those with asthma. However, endothelial function and
systemic inflammation are similar between physical activity and
fitness-matched subjects with and without asthma, suggesting
that mild controlled asthma alone does not contribute to
increased systemic inflammation and/or impaired vascular
function and that previous results showing impaired endothelial
function and systemic inflammation in those with asthma may be
explained by differences in baseline fitness and/or physical
activity.
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Clinical laboratories worldwide need to report
IgE antibody results on clinical specimens as
analytical results and not use differential
positive thresholds
To the Editor:
I have followedwith great interest the discussion between Scala
and Sopo1 and Tripodi et al2 related to the appropriate threshold
that should be used in reports of serologic testing to define a pos-
itive allergen-specific IgE antibody level. Should it be 0.7, 0.35, or
0.1 kUA/L? The use of a variable positive threshold for research
studies3 in which receiver operator characteristics curves are
used is understandable. However, when IgE antibody results are
reported on clinical serum specimens for use in the diagnostic
workup of a patient, the same defined negative/positive cutoff
should be used by all clinical immunology laboratories world-
wide when using a particular assay method. This approach would
treat the IgE antibody measurement as an analytical measurement
that it is instead of suggesting that it inherently has value in
defining the presence of allergic disease.
This issue has become a problem for clinicians practicing in the
United States. It has recently been noted that 47.6% of approxi-
mately 300 participants (among them federally licensed clinical
laboratories) in a widely subscribed external proficiency survey4
report allergen-specific IgE results only down to a historical cutoff
of 0.35 kUA/L. Thus, for some laboratories, IgE antibody level ofless than 0.35 kUA/L is reported as an undetectable result. In
contrast, 34.1% of the participants currently report IgE antibody re-
sults down to the US Food and Drug Administration–cleared
analytical sensitivity of 0.1 kUA/L. This makes IgE antibody levels
of less than 0.1 kUA/L undetectable for these laboratories. The re-
maining approximately 18% of the participants in the survey report
that they use different positive/negative cutoff levels. One con-
founding variable in the use of these data is that theywere generated
using responses from laboratories using a number of different US
Food and Drug Administration–cleared IgE antibody singleplex
IgE antibody assays. Interestingly, 10% of the participants in the
survey indicated that they could actually report a ‘‘positive predic-
tive value’’ or the level of IgE antibody above which they consid-
ered allergic disease was likely. The concerns raised by Scala and
Sopo,1 addressed by Tripodi et al,2 and discussed in the US data
set4 are troubling because they emphasize the continued wide-
spread use of differential reporting schemes for allergen-specific
IgE antibody. Clinical laboratory directors who perform diagnostic
allergy testing, particularly in theUnited States, do not appear to un-
derstand the limitations of the allergen-specific IgE result that must
beviewedwithin the context of patient’s history to be of any clinical
value. Allergen-specific IgE antibody whether measured in the
blood by serologic assays or in the skin by puncture or intradermal
skin test techniques is simply an indicator of sensitization (IgE anti-
body positivity) to a particular allergen specificity.5 It does not by
itself define allergic disease, no matter how many ‘‘predictive’’
probability of disease versus IgE antibody concentration plots are
reported by investigators for different allergen specificities. IgE
antibody positivity is simply one of many risk factors that need to
be factored into the decision process by the practicing clinician
when they combine diagnostic test results with their patient’s his-
tory and physical examination data. Historically, 0.35 kUA/L was
the reported IgE antibody threshold (medical decision point) that
was used to identify individuals with ‘‘clinically evident allergic
disease.’’ In recent years, a lower limit of quantitation for clinically
used autoanalyzer-based IgE assays, which has been blessed by
regulatory agencies, has been assigned as 0.1 kUA/L. This has re-
sulted in IgE antibody levels that are reported between 0.1 and
0.35 kIUA/L, which will not always correlate with clinically
evident allergic disease. To illustrate the value of IgE antibodies
in this range, Linden et al6 showed using Youden plots that optimal
performance (diagnostic sensitivity and specificity) of cat and dog
specific IgE antibody levels was achieved in their study at 0.12 and
0.2 kUA/L, respectively, with a widely used singleplex assay. How-
ever, in general, IgE antibody levels between 0.1 and 0.35 kUA/L
must be cautiously interpreted by the clinician within the context
of clinical symptoms because their clinical significance remains
unknown. A recommendation to clinical laboratories by a 2015
consensus guidance document on this issue5 is that all clinical lab-
oratories report their IgE antibody results as analytical measure-
ments down to the regulatory accepted lower limit of
quantitation of the assay (also known as the assay’s ‘‘analytical
sensitivity’’). For the United States, this is 0.1 kUA/L for the 3 prin-
cipal singleplex autoanalyzers. Then, the clinicianmay incorporate
the IgE antibody results with environmental exposure, patient his-
tory, physical examination, and other relevant data to derive a like-
lihood of allergic disease. Clinical laboratories need to provide
analytical measurements of IgE antibody that are as close to
‘‘truth’’ as technically achievable by their assay system and then
let the clinician judge themeasurement’s utility inmaking the diag-
nosis. This is the recommended approach rather than each
METHODS
This study (protocol no. Pro00029773) was approved by the University of
Alberta Health Research Ethics Board. Written consent was obtained from all
subjects before participation in the study.
Subjects
Men and women with asthma (n5 16) between the ages of 18 and 45 years
and with a body mass index of 30 kg/m2 or less were recruited from the Uni-
versity of Alberta Asthma Clinic and The Lung Health Clinic, Edmonton, Al-
berta, Canada. Asthma diagnosis was based on history of asthma symptoms
such as recurrent episodes of wheezing, chest tightness, shortness of breath,
and 1) 12%or less and 200mL improvement in FEV1 postbronchodilator,
E1,E2
2) a positive methacholine challenge (PC20 <_ 4 mg/mL
2), or 3) 10% or more
decrease in FEV1 after an exercise challenge.
E2,E3 Asthma control was evalu-
ated according to the AsthmaControl QuestionnaireE4,E5 at the time of the first
visit and only those with controlled (Asthma Control Questionnaire score of
<0.75) and partly controlled (Asthma Control Questionnaire score of 0.75-
1.5) asthma were included. Age, body mass index, and physical activity/
fitness-matched control subjects (n 5 16) without asthma (asymptomatic
and as demonstrated by negative responses to all 3 the tests described above)
were recruited from the general population. Subjects were excluded if demon-
strating the following cardiovascular risk factors: hypertension (defined as
resting systolic blood pressure of 140 mmHg or more and/or diastolic blood
pressure of 90 mmHg or more),E6 a family history of sudden cardiac death
or known coronary heart disease, elevated cholesterol levels (measured with
CardioCheck capillary blood analyzer, Chek Diagnostics, Indianapolis, In-
d),E7,E8 diabetes or impaired fasting glucose, smoking history (current
smokers or persons who quit smoking within <6 months were excluded),E6
or 1 or more reason(s) to withhold from physical activity according to the
Physical Activity Readiness Questionnaire (PAR-Q) and You Question-
naire.E7 Because coexisting allergies do not increase the risk of CVD in asth-
maE9 but may influence the systemic inflammatory profile,E10,E11 both atopic
and nonatopic subjects were recruited and previously known allergies noted.
Fractions of exhaled nitric oxide (NIOX MINO, Aerocrine, Inc, Solna, Swe-
den) were used for the evaluation of pulmonary inflammation, and the risk
of obstructive sleep apnea was defined as having 3 or more risk factors occur-
ring on the STOP-Bang questionnaire.E12,E13
Measurements
Aerobic fitness. A graded cardiopulmonary exercise test was performed
to determine the rate of oxygen consumption at maximal exercise (V
:
O2max).
The test was performed on a cycle ergometer (Ergoselect 200, Ergoline,
Bitz, Germany) at incremental stages of 25 W until exhaustion. Breath-by-
breath analysis of pulmonary gases was performed throughout the test using
the Vmax Metabolic Cart (CareFusion, Yorba Linda, Calif). The subjects
were asked to rate their level of perceived exertion at 2-minute intervals during
the test, expressed on the modified Borg scale from 1 (nothing at all) to 10
(maximal). The highest V
:
O2 reading (30 seconds time average) was reported
as V
:
O2max as a measurement of cardiopulmonary fitness.
E14
Physical activity. Physical activity was quantified as the number of steps
taken and energy expenditure through the use of physical activity monitors
(biaxial accelerometers, SenseWear Pro3 Armband, Bodymedia, Milan, Italy).
SenseWearProaccelerometershavepreviouslybeenshown toaccuratelymeasure
energy expenditureE15,E16 and have been used in research with patients with res-
piratory diseases.E17The subjectswere instructed towear the activitymonitors on
the back of their dominant upper arm for the entire day for a total of 3 days, pref-
erably 2 weekdays and 1 day of the weekend. Data from the armbands were
analyzed using SenseWear software (version 7.0.0.2378, Bodymedia).
Endothelial function. All endothelial function and arterial stiffness
data were collected at the same time of day in the morning after a 12-hour
fasting period.E18,E19 When applicable, the subjects were asked to withhold
any long-acting beta agonists and/or corticosteroid medications for a mini-
mum of 48 hours before the test and short-acting beta agonists for 12 hours
before the test. No subjects were treated for medical conditions other than
asthma, and decongestants were not taken within days before the study.
The endothelial function of the brachial artery was evaluated at room temper-
ature after 10 minutes of rest in the supine position using ultrasound imaging
(8L-RS 4.0-13.0MHz probe, Vivid Q, GE Healthcare, Mississauga, Ontario,
Canada). Baseline diameter of the brachial artery was established, and the
blood flow of the forearm was subsequently occluded distally of the
measuring site for a duration of 5 minutes. The blood velocity and the
brachial diameter were monitored for 20 seconds before and 3 minutes after
cuff-release, and later analyzed offline (Medical Imaging Applications, LLC,
Coralville, Iowa; EchoPAC PC software, version 110, GE Healthcare,
Horten, Norway). Microvascular function was evaluated as the velocity
time integral (cm/s) envelope of the first heartbeat of reactive hyperemia.E20
The total shear stress after reactive hyperemia was calculated as 8 3 mean
velocity until peak FMD/(baseline diameter/10).E18 All FMD tests were
done by the same person. Changes within the vessel diameters were evaluated
by 2 independent investigators. The interinterpreter correlation coefficients
for baseline, peak, and peak % baseline diameter were r 5 0.96, 0.97, and
0.72, respectively.
Arterial stiffness. Arterial stiffness was evaluated by the PWV between
the radial and the carotid arteries using applanation tonometry (Mikro-tip
Catheter Transducers model SPT-301, Millar Instruments, Inc, Houston,
Texas). The carotid and radial pulses were obtained after 10 minutes of supine
rest at room temperature, whereby PWV was recorded simultaneously over
the 2 measuring sites. Approximately 30 waveforms were recorded from each
subject, and 10 consecutive waveforms were selected for analysis (LabChart
version 7.3.5, ADInstruments, New South Wales, Australia). The distance
between measuring points was divided by the average difference in time
between corresponding carotid-radial waveforms, as per guidelines.E21
Blood collection. Blood was collected via an antecubital venipuncture
immediately after the vascular function test. Once collected, resting
glucose and cholesterol levels were measured immediately, and the blood
was then allowed to clot at room temperature for a minimum of 30 minutes
before being centrifuged at 1000g for 10 minutes at 48C. Aliquots were
outsourced to Eve Technologies (Calgary, Alberta, Canada) for analysis
of inflammatory markers (ie, IL-6, C-reactive protein, and tumor necrosis
factor-alpha).
Statistical analysis
Data are presented as mean 6 SD unless otherwise stated. For all
inferential analyses, the probability of type I error was set at 0.05. Subject
characteristics and vascular parameters were compared between those with
asthma and controls using 2-tailed independent samples t tests. Binominal
variables were compared between those with asthma and controls using the
chi-square test. The relationships between serum levels of tumor necrosis
factor-alpha, IL-6, and C-reactive protein, and FMD/total shear stress after
reactive hyperemia and PWV were evaluated in those with asthma using the
Pearson product-moment correlation coefficient (r). Based on previous
studies,E22 a sample size of 16 in each group was sufficient to detect a
10% difference in FMD between those with asthma and controls, corre-
sponding to a more than 50% increase in the relative risk of CVDE23
(a 5 0.05; b 5 0.8). All statistical analyses were performed using Statis-
tical Package for the Social Sciences (SPSS Statistics, IBM, version 20.0,
Armonk, NY).
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FIG E1. Relationship between endothelial function and systemic inflammation—FMD/SSRHtotal vs (A) IL-6,
P5 .65, (B) TNF-a, P5 .22, and (C) CRP, P5 .32—and arterial stiffness and systemic inflammation—PWV vs.
(D) IL-6, r5 0.57, P < .05, (E) TNF5 a, P5 .50, and (F) CRP, P5 .55—in subjects with asthma. CRP, C-reactive
protein; SSRHtotal, total shear stress after reactive hyperemia; TNF-a, tumor necrosis factor-alpha.
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